| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcbc66753bccef24ea0dbc6694e9bbc7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ab027c7a57d644ef9ac2d6aee584655
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2bc568495408f5943df39b9f60d2fcf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_785ac2b35073f5a6d251678e6fb31b6f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-712
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
2012-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8935bfd27bb5f4bada0b7e93bb08950d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_214816d97fd43dee375e543109d29b46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80fe1ee2c8a1b5a0812d39e0b8875e9c |
| publicationDate |
2013-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2013070771-A1 |
| titleOfInvention |
Administration of factor xi antisense oligonucleotides |
| abstract |
Disclosed herein are methods of administering pharmaceutical compositions comprising a modified antisense oligonucleotide for decreasing Factor XI activity and decreasing Factor XI antigen. Also disclosed herein are methods of administering pharmaceutical compositions comprising a modified antisense oligonucleotide for treating or preventing thromboembolic and inflammatory disorders in a subject in need thereof. Such pharmaceutical compositions comprising an antisense oligonucleotide targeting Factor XI can also be used as a prophylactic treatment to prevent subjects at risk for thromboembolic and inflammatory conditions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633482-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3799604-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014076195-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10772906-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3406718-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11660347-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11376273-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11492620-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11021710-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10077443-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014118267-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155816-B2 |
| priorityDate |
2011-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |